A novel recombinant antibody specific to full-length stromal derived factor-1 for potential application in biomarker studies

作者：Bromage Daniel I; Taferner Stasa; Pillar Mahesh; Yellen Derek M; Davidsonr Sean M^*

来源：PLos One, 2017, 12(4): e0174447.

DOI：10.1371/journal.pone.0174447

Background
Stromal derived factor-1 alpha (SDF-1 alpha/CXCL12) is a chemokine that is up-regulated in diseases characterised by tissue hypoxia, including myocardial infarction, ischaemic cardiomyopathy and remote ischaemic conditioning (RIC), a technique of cyclical, non-injurious ischaemia applied remote from the heart that protects the heat from lethal ischaemia-reperfusion injury. Accordingly, there is considerable interest in SDF-1 alpha as a potential biomarker of such conditions. However, SDF-1 alpha is rapidly degraded and inactivated by dipeptidyl peptidase 4 and other peptidases, and the kinetics of intact SDF-1 alpha remain unknown.
Methods & results
To facilitate investigation of full-length SDF-1 alpha we established an ELISA using a novel recombinant human antibody we developed called HCI.SDF1. HCI.SDF1 is specific to the N-terminal sequence of all isoforms of SDF-1 and has a comparable KD to commercially available antibodies. Together with a detection antibody specific to the a-isoform, HCI.SDF1 was used to specifically quantify full-length SDF-1 alpha in blood for the first time. Using RIC applied to the hind limb of Sprague-Dawley rats or the arms of healthy human volunteers, we demonstrate an increase in SDF-1 alpha using a commercially available antibody, as previously reported, but an unexpected decrease in full-length SDF-1 alpha after RIC in both species.
Conclusions
We report for the first time the development of a novel recombinant antibody specific to fulllength SDF-1. Applied to RIC, we demonstrate a significant decrease in SDF-1 alpha that is at odds with the literature and suggests a need to investigate the kinetics of full-length SDF-1 alpha in conditions characterised by tissue hypoxia.

• 出版日期2017-4-5